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Fibroid, also called leiomyomas, is common tumor of the uterus. Usually, 
women of reproductive age are at risk of getting it. However, majority of these 
women develop fibroid (s) by the age of 50 years. This condition usually causes 
painful and unpleasant symptoms such as; heavy bleeding, prolonged periods, 
inter-menstrual bleeding, abdominal pain and cramps, anemia, pelvic pain and 
pain during sexual intercourse, among others. Abnormal bleeding, such as bleed-
ing that occurs with fibroids and heavy periods, often lasts more than 10 days per 
month. This fibroid symptom involves persistent bleeding between cycles, which 
can severely impact one’s quality of life. Abnormal bleeding, especially in fibroids, 
can be taken as missing three or more periods in a woman who had been having 
regular monthly period, or periods that last less than 21 days or more than 35 days 
apart from each other. Another indication of an abnormal period is bleeding 
through multiple pads and tampons in a short amount of time.
Keywords: per vaginal bleeding, abnormal bleeding, normal bleeding,  
menstrual bleeding, menstrual cycle
1. Introduction
In a normal adult human – female, menstrual cycle occurs to provide for release 
of oocyte, thus preparing the uterus for any possible pregnancy [1].
Thus, menstruation is a woman’s normal monthly per vaginal bleeding, usually 
called “monthly period.” When a woman menstruates, her body discards the monthly 
build-up of the lining of the uterus. The resultant blood, also called menstrual blood, 
and uterine tissues flow from the uterus through the cervix and then into the vagina 
and eventually out of the body [2]. In other words, menstruation is the cyclic and 
orderly sloughing off of the uterine lining which occurs in response to the interac-
tions of hormones produced by the hypothalamus, pituitary and ovaries [3].
Menstrual cycle is, thus, divided into three phases. These are follicular or prolif-
erative phase, ovulation and luteal or secretory phase. The number of days between 
the first day of menstrual bleeding of a woman’s cycle to the onset of menses of the 
next cycle is referred to as ‘the length of a menstrual cycle’. The average duration of 
a menstrual cycle is usually 28 days. However, some women may have shorter cycle 
of 21 days. Such women are referred to as ‘polymenorrheic women’. Some women 
also have longer cycle of 35 days or more. These are called oligomenorrheic women 
[3]. Thus, the complete cycle may last anywhere from 21 days to 35 days with an 
average duration of 28 days for most women.
Menstruation begins at puberty, usually between ranging 10 to 16 years of age 
of a normal girl child. It ends at menopause, corresponding to average age of 45 to 
55 years of a normal adult female [1].
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Ordinarily, the typical volume of blood lost during menstruation is approxi-
mately 30 milliliters (mL). Any amount of blood lost during menstruation which is 
greater than 80 mL is considered abnormal [4].
2. Physiology of normal uterine bleeding
There are four major circulating hormones involved in the menstrual cycle. 
These hormones are; follicle stimulating hormones (FSH), luteinizing hormones 
(LH), estradiol (estrogen) and progesterone. The concentrations of these hormones 
in blood vary and their levels provide characteristic changes during the menstrual 
cycle [5]. In particular, the body makes three main types of estrogen; estrone (E1), 
estradiol (E2) and estriol (E3). E1 is the only estrogen the body makes after meno-
pause. E2 is the most common type in women of childbearing age whereas E3 is the 
main estrogen during pregnancy [6].
The menstrual cycle is triggered by the gonadotropin-releasing hormone 
(GnRH) pulse generator in the hypothalamus. The GnRH pulse generator then 
releases gonadotropin-releasing hormone (GnRH) [7]. This GnRH in turn stimu-
lates the synthesis and release of the gonadotropins, luteinizing hormones (LH) 
and follicle stimulating hormones (FSH), from the anterior pituitary gland [5]. 
LH and FSH exert their effects in the ovaries. There are two types of cells respon-
sible for hormone production within the ovarian follicle; theca cells and granulosa 
cells. LH acts on theca cells to produce progesterone and androstenedione. The 
enzyme involved is cholesterol desmolase. Upon secretion of androstenedione, 
the hormone diffuses to granulosa cells. FSH then stimulates the granulosa cells 
to convert androstenedione to testosterone and eventually 17-beta-estradiol. The 
enzyme involved is aromatase. The levels of 17-beta-estradiol or progesterone 
increases accordingly, depending on the phase of the menstrual cycle. This 
increase triggers a negative feedback back to the anterior pituitary to lower the 
levels of FSH and LH which are being produced and subsequently, the levels of 
17-beta-estradiol and progesterone produced. The only exception occurs during 
ovulation, in which case, once a critical amount of 17-beta-estradiol is produced it 
provides positive feedback to the anterior pituitary instead of a negative feedback 
[5, 6]. This positive feedback results in increased amounts of FSH and LH, hence 
the LH surge bringing about ovulation [1].
The onset of the menstrual cycle, or menarche, usually at 10–16 years, begins 
at puberty and ceases at menopause, usually 45–55 years. The cycle has 3 phases: 
follicular or proliferative phase, ovulation and luteal or secretory phase [1, 5].
Follicular Phase: Usually, the first phase of the menstrual cycle is the follicular 
or proliferative phase. The phase is characterized by menstruation, resulting from 
shedding off of the initially thickened endometrial lining following failed fertiliza-
tion or implantation. It occurs from day zero to day 14 of the menstrual cycle (see 
Figures 1 and 2), based on the average duration of 28 days cycle. There is usually 
variability in the length of menstrual cycle and this is due to variations in the 
length of the follicular phase. The main hormone during this phase is estrogen, in 
particular 17-beta-estradiol [1, 5] from the ovary coupled with follicle stimulating 
hormone (FSH), released from anterior pituitary gland. Upon release from anterior 
pituitary, FSH and LH slowly rise in levels and cause the growth of follicles on the 
surface of the ovary. This process prepares the egg for ovulation. As the follicles 
grow, they begin releasing estrogens and a low level of progesterone. These ovar-




negative feedback process (See Figure 3). Thus, as the follicular phase progresses to 
the end, the increased amounts of 17-beta-estradiol will provide negative feedback 
to the anterior pituitary.
Due to the rise of FSH during the first days of the menstrual cycle or follicular 
phase, several ovarian follicles are stimulated. These ovarian follicles compete with 
each other for dominance. The follicle that reaches maturity is called a Graafian 
Figure 1. 





follicle. During follicular phase, estrogen suppresses production of luteinizing 
hormone (LH) from the pituitary gland (Figures 4 and 5) [5].
Ovulation phase: Ovulation phase comes next. Ovulation occurs 14 days 
later after the first day of menstruation [1]. This means that with an average 
28-day cycle, ovulation occurs on day 14 (see Figure 1).
At the end of the proliferative phase, 17-beta-estradiol (E2) levels are high due to 
the follicle maturation. During the follicular phase, estrogen suppresses production 
of luteinizing hormone (LH) from the pituitary gland but in this phase it stimulates 
Figure 3. 
The follicular phase [5].
Figure 4. 




maturation a follicle and thickens the endometrial lining. At this time, only 17-beta-
estradiol (E2) provides positive feedback for FSH and LH production. A critical level 
of 17-beta-estradiol must be reached, at least 200 picograms per milliliter of plasma, 
to cause this positive feedback. The high levels of FSH and LH present during this 
time is called the LH surge [5]. The release of LH matures the ovum much further 
and weakens the wall of the follicle in the ovary, thus causing the fully developed 
follicle to release its secondary oocyte, in a process known as ovulation. After being 
released from the ovary, the ovum, also called egg, is swept into the fallopian tube.
The changes to the cervix which was initiated during the follicular phase is 
even further increased in ovulation phase allowing for increased, waterier cervical 
mucus in order to better accommodate the possible sperm. The levels of 17-beta-
estradiol fall at the end of ovulation [1, 5, 6].
Luteal or Secretory phase: The luteal phase follows ovulation. It is characterized 
by the development of corpus luteum, secretion of progesterone and the formation 
of thick mucus which blocks the cervix. Blocking of the cervix is in anticipation that 
implantation has occurred [5]. Luteal phase always occurs from day 14 to day 28 of 
the cycle (See Figure 1). Progesterone stimulated by LH is the dominant hormone 
during this phase to prepare the corpus luteum and the endometrium for possible 
implantation of the fertilized ovum. As the luteal phase comes to an end, progester-
one will provide negative feedback to the anterior pituitary to decrease FSH and LH 
levels and subsequently, the 17-beta-estradiol (E2) and progesterone levels [1, 5, 6].
Therefore, at the end of luteal phase, in the absence of implantation (preg-
nancy), when the level of progesterone drops, menses or menstruation occurs [1]. 
See Figure 2.
3. Clinical significance of physiology of normal uterine bleeding
A normal woman has an average of 450 menses throughout her lifetime. It is 
therefore, very important to fully understand the menstrual cycle and its physiology 
Figure 5. 
The luteal phase [5].
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as various complications may occur later in life for a woman [8]. The knowledge of 
this forms the cornerstone of making appropriate diagnosis and investigation [9].
Menstruation begins at puberty, usually between 10 to 16 years of age of a nor-
mal girl child. It ends at menopause, corresponding to average age of 45 to 55 years 
of a normal adult female [1].
Ordinarily, the typical volume of blood lost during menstruation is approxi-
mately 30 milliliters (mL). Any amount of blood lost during menstruation which is 
greater than 80 mL is considered abnormal [4].
The clinician needs to know all these in order to make appropriate diagnosis and 
investigation. Anything sort of this could result in gross errors.
4. Bleeding in fibroids
Fibroids are growths of muscle and fibrous tissue in or on the wall of the uterus.
They range in size from seedlings which are undetectable by human eye, to 
bulky masses that can disfigure or enlarge the uterus. One can have a single fibroid 
or multiple fibroids (See Figure 6) [10].
4.1 Normal versus abnormal bleeding
It is usually very difficult to tell between what is normal and what is abnormal 
when it comes to menstruation. This is because of the huge variation in women to 
the point that what is normal for one might be abnormal for another. Heavy men-
strual flow is highly subjective.
In addition to the above, there are many factors that influence length, heaviness, 
and frequency of a woman’s menstrual flow. Thus, paying close attention to one’s 
monthly period and observing the trend becomes paramount to detecting whether 
or not one has abnormal or normal menstrual flow. This observance might need to 
have been done over a significant period of time [11].
Vaginal bleeding is considered to be abnormal if it occurs between a woman’s 
menstrual cycles, in situations where flow is significantly heavier than normal for a 
particular individual or when it occurs after menopause.
4.1.1 Normal bleeding
Bleeding in normal period typically lasts between 3 and 8 days, usually with a 
heavier menstrual flow for the first two days. The flow gets increasingly lighter as 
Figure 6. 




the number of days progress. Women with normal periods may have limited spot-
ting, cramps that ache and bloating that goes away once the period is over.
4.1.2 Abnormal periods or fibroids bleeding
On another hand, abnormal bleeding, such as those bleedings occurring in 
fibroids and in heavy periods, usually lasts more than 10 days per month. Fibroid 
symptom involves persistent bleeding between menstrual cycles. This is to the point 
that can severely affect one’s quality of life [11].
Abnormal bleeding can be considered missing 3 or more periods in a row, or 
periods which occur less than 21 days or more than 35 days apart from each other. 
Another sign of an abnormal period is bleeding through multiple pads and tampons 
in a short amount of time [10, 11].
4.2 The cause of heavy bleeding in fibroids
The cause of heavy bleeding in fibroid is not well understood. Since fibroids 
are connected to your uterine lining, the fibroids can exert pressure against the 
uterine wall and cause the endometrial tissue to bleed more than normal [11]. 
See Figure 6.
During menstrual period, the uterine lining sheds off and the uterus has two 
basic mechanisms to stop itself from bleeding. The first mechanism is through the 
normal blood-clotting working throughout the body by forming plugs within the 
blood vessels. Secondly, since the uterus is a muscle, it also has the ability to con-
tract the bleeding vessels of the uterus, thus stopping the bleeding. The contractions 
are associated with menstrual cramps.
However, it is believed that fibroids interfere with adequate and proper con-
traction of the uterus. In this way, it does not stop menstrual bleeding adequately. 
Additionally, fibroids produce growth factors (proteins) that stimulate relaxation of 
the uterine blood vessels and thus causing more blood in the uterine cavity, which 
leads to heavier periods [11].
4.3 Treatment of abnormal bleeding and fibroids bleeding
The treatment of abnormal bleeding depend on; the cause, patient age, severity 
of bleeding and whether one wants to have children or not [12].
Otherwise, the common medical treatment options are;
1. Use of birth control pills
2. Hormone injections or a hormone-releasing IUD (intra-uterine device)
3. Surgery to control bleeding or to remove growths, such as fibroids, that are 
causing the bleeding. Surgical options available include endometrial ablation, 
endometrial polyp removal, myomectomy or even hysterectomy
The two medical treatments for heavy menstrual bleeding have been effective 
enough. First, levonorgestrel intra-uterine system was FDA approved for the treat-
ment of heavy menstrual bleeding in 2009. It is highly effective for decreasing men-
strual bleeding, treating anemia and improving the overall quality of life. Secondly, 
tranexamic acid, also FDA approved for heavy menstrual bleeding in 2009, reduces 
menstrual blood loss in 40% of women and improves quality of life. Moreover, in 
women with fibroids, tranexamic acid has been shown to decrease heavy menstrual 
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5. Conclusion
Research on bleeding in fibroids is still far from over. Much more is still wanting.
Uterine fibroids are common debilitating problems for many women. Almost 
60% of women with fibroids report that symptoms affect their quality of life and 
impede their physical activity. Again, 24% of them report that fibroid symptoms 
prevent them from reaching their full potential at work. Heavy menstrual bleeding, 
which is the most common symptom of uterine fibroids, affects approximately 
1.4 million women per year.
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